201 related articles for article (PubMed ID: 27984757)
1. Therapeutic effect of ursolic acid in experimental visceral leishmaniasis.
Jesus JA; Fragoso TN; Yamamoto ES; Laurenti MD; Silva MS; Ferreira AF; Lago JH; Santos-Gomes G; Passero LF
Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):1-11. PubMed ID: 27984757
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis.
Bilbao-Ramos P; Serrano DR; Ruiz Saldaña HK; Torrado JJ; Bolás-Fernández F; Dea-Ayuela MA
Molecules; 2020 Mar; 25(6):. PubMed ID: 32204358
[TBL] [Abstract][Full Text] [Related]
3. Related Pentacyclic Triterpenes Have Immunomodulatory Activity in Chronic Experimental Visceral Leishmaniasis.
de Jesus JA; Laurenti MD; Antonangelo L; Faria CS; Lago JHG; Passero LFD
J Immunol Res; 2021; 2021():6671287. PubMed ID: 33681389
[TBL] [Abstract][Full Text] [Related]
4. In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative.
de Almeida L; Passalacqua TG; Dutra LA; Fonseca JNVD; Nascimento RFQ; Imamura KB; de Andrade CR; Dos Santos JL; Graminha MAS
Biomed Pharmacother; 2017 Nov; 95():536-547. PubMed ID: 28866421
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.
Asad M; Bhattacharya P; Banerjee A; Ali N
BMC Infect Dis; 2015 Apr; 15():188. PubMed ID: 25884796
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
7. LEISHMANICIDAL ACTIVITY in vivo OF A MILTEFOSINE DERIVATIVE IN Mesocricetus auratus.
da Silva JC; Nunes JB; Gontijo VS; Malaquias LCC; de Freitas RP; Alves RB; Colombo FA; Laurenti MD; Marques MJ
Acta Trop; 2020 Sep; 209():105539. PubMed ID: 32461110
[TBL] [Abstract][Full Text] [Related]
8. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
Banerjee A; De M; Ali N
J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
[TBL] [Abstract][Full Text] [Related]
9. Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system.
Duarte MC; Lage LM; Lage DP; Martins VT; Carvalho AM; Roatt BM; Menezes-Souza D; Tavares CA; Alves RJ; Barichello JM; Coelho EA
Parasitol Int; 2016 Dec; 65(6 Pt A):728-736. PubMed ID: 27425599
[TBL] [Abstract][Full Text] [Related]
10. Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.
Freitas EO; Nico D; Alves-Silva MV; Morrot A; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004297. PubMed ID: 26701750
[TBL] [Abstract][Full Text] [Related]
11. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.
Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Raposo R; Méndez MT; Torrado-Santiago S; Torrado JJ
Antimicrob Agents Chemother; 2004 Sep; 48(9):3246-52. PubMed ID: 15328080
[TBL] [Abstract][Full Text] [Related]
12. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
13. Treatment with triterpenic fraction purified from Baccharis uncinella leaves inhibits Leishmania (Leishmania) amazonensis spreading and improves Th1 immune response in infected mice.
Yamamoto ES; Campos BL; Laurenti MD; Lago JH; Grecco Sdos S; Corbett CE; Passero LF
Parasitol Res; 2014 Jan; 113(1):333-9. PubMed ID: 24173812
[TBL] [Abstract][Full Text] [Related]
14. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
Mendonça DVC; Martins VT; Lage DP; Dias DS; Ribeiro PAF; Carvalho AMRS; Dias ALT; Miyazaki CK; Menezes-Souza D; Roatt BM; Tavares CAP; Barichello JM; Duarte MC; Coelho EAF
Exp Parasitol; 2018 Mar; 186():24-35. PubMed ID: 29448040
[TBL] [Abstract][Full Text] [Related]
15. Antileishmanial activity of nano-amphotericin B deoxycholate.
Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Assessment of Ursolic Acid Loaded into Nanostructured Lipid Carriers in Experimental Visceral Leishmaniasis.
Jesus JA; Sousa IMO; da Silva TNF; Ferreira AF; Laurenti MD; Antonangelo L; Faria CS; da Costa PC; de Carvalho Ferreira D; Passero LFD
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34205283
[TBL] [Abstract][Full Text] [Related]
17. Anti-leishmanial activity of the bisnaphthalimidopropyl derivatives.
Tavares J; Ouaissi A; Silva AM; Lin PK; Roy N; Cordeiro-da-Silva A
Parasitol Int; 2012 Jun; 61(2):360-3. PubMed ID: 22155672
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic Potential of Eugenol Emulsion in Experimental Visceral Leishmaniasis.
Islamuddin M; Chouhan G; Want MY; Ozbak HA; Hemeg HA; Afrin F
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005011. PubMed ID: 27776125
[TBL] [Abstract][Full Text] [Related]
19. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
[TBL] [Abstract][Full Text] [Related]
20. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
